Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Breast Cancer Invasive Nos × Triptorelin Pamoate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 19 Breast Neoplasms 6 Salivary Gland Neoplasms 1 Prostate Adenocarcinoma 1 Neoplasms 1 Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel 1 Drug-Related Side Effects and Adverse Reactions 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Cancer Invasive Nos 1 Adenocarcinoma 1

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 Triptorelin Pamoate 1 Letrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02005887 2019-05-29

TREND

ETOP IBCSG Partners Foundation

Phase 2 Completed

51 enrolled 10 charts

Breast Cancer Invasive Nos

Data powered by HemOnc (CC BY 4.0) Colophon ⚡